Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dulaglutide

dulaglutide

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dulaglutide

32 trials tracked of dulaglutide: 21 in phase 3 or 4 and 14 with published results. The most-cited published study has 790 citations.

32Trials tracked
21Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 6 Phase 3 15 Phase 2 4 Phase 1 7
  1. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 790 cited
  2. Phase 3 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed · 643 cited
  3. Phase 3 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus Completed · 267 cited
  4. Phase 3 A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes Completed · 226 cited
  5. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 210 cited
  6. Phase 3 A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Completed · 198 cited
Show 26 more trials
  1. Phase 3 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes Completed · 150 cited
  2. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Completed · 84 cited
  3. Phase 4 A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Completed · 20 cited
  4. Phase 3 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed · 20 cited
  5. Phase 3 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Completed · 14 cited
  6. Phase 4 A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes Completed · 11 cited
  7. Phase 4 A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Completed · 10 cited
  8. Phase 4 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc Completed · 5 cited
  9. Phase 4 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Completed
  10. Phase 4 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India Completed
  11. Phase 3 A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes Completed
  12. Phase 3 A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes Completed
  13. Phase 3 A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus Completed
  14. Phase 3 A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus Completed
  15. Phase 3 Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) Completed
  16. Phase 2 A Study of LY3437943 in Participants With Type 2 Diabetes Completed
  17. Phase 2 A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Completed
  18. Phase 2 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Completed
  19. Phase 2 A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus Completed
  20. Phase 1 A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants Completed
  21. Phase 1 A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) Completed
  22. Phase 1 A Study of LY3493269 in Participants With Type 2 Diabetes Completed
  23. Phase 1 A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants Completed
  24. Phase 1 A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants Completed
  25. Phase 1 A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe Completed
  26. Phase 1 A Study of Dulaglutide in Chinese Participants Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes
Diabetes & Endocrinology RCT
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes For people struggling with diabetes on dulaglutide, could switching drugs help?
This subgroup analysis of a phase IV RCT examined adults with type 2 diabetes inadequately controlled on dulaglutide.
Switching from dulaglutide to tirzepatide led to greater drops in blood sugar and body weight for adults with type 2 diabetes after 40 weeks…
Apr 8, 2026
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Nutrition & Obesity Medicine Meta-analysis
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Apr 8, 2026
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
Cardiology Meta-analysis
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
Apr 6, 2026
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Diabetes & Endocrinology Cohort
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…
medRxiv Apr 4, 2026